Urogen Pharma $URGN Shares Purchased by Hennion & Walsh Asset Management Inc.

Key Points

• Institutional ownership increased: Hennion & Walsh Asset Management raised its Urogen Pharma stake by 50.8% to 276,696 shares, while institutional investors collectively own 91.29% of the company.
• Urogen reported mixed quarterly results: Revenue of $72.46 million exceeded estimates of $63.55 million, but its $0.28 per-share loss was slightly wider than the expected $0.26 loss.
• Analysts remain broadly optimistic: Guggenheim and TD Cowen raised their price targets to $58 and $60, respectively. The stock has a “Moderate Buy” consensus rating and an average target price of $48.78, while HC Wainwright raised its longer-term earnings forecasts and expects earlier profitability.

Hennion & Walsh Asset Management Inc. raised its position in Urogen Pharma (NASDAQ:URGN - Free Report) by 50.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 276,696 shares of the company's stock after acquiring an additional 93,192 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.57% of Urogen Pharma worth $10,182,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of URGN. Swiss National Bank purchased a new position in Urogen Pharma during the 1st quarter worth approximately $1,399,000. SG Americas Securities LLC lifted its stake in Urogen Pharma by 20.3% in the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company's stock valued at $29,808,000 after buying an additional 280,199 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in Urogen Pharma by 139.1% in the first quarter. ADAR1 Capital Management LLC now owns 395,459 shares of the company's stock valued at $7,110,000 after buying an additional 230,084 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in shares of Urogen Pharma by 8.8% in the fourth quarter. Rice Hall James & Associates LLC now owns 281,876 shares of the company's stock valued at $6,602,000 after acquiring an additional 22,733 shares during the period. Finally, Elmind Capital LP acquired a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $2,342,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Trading Up 3.0%

NASDAQ:URGN opened at $46.96 on Friday. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $48.19. The stock's 50 day simple moving average is $36.44 and its 200-day simple moving average is $27.12. The firm has a market cap of $2.30 billion, a P/E ratio of -23.72 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analysts' expectations of $63.55 million. Research analysts forecast that Urogen Pharma will post -0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on URGN. Guggenheim lifted their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a "buy" rating in a report on Thursday. TD Cowen increased their price target on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a "buy" rating in a research note on Wednesday. UBS Group reissued a "buy" rating on shares of Urogen Pharma in a research report on Thursday, July 9th. The Goldman Sachs Group restated a "neutral" rating and issued a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. Finally, LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a report on Monday, May 11th. They issued a "buy" rating and a $43.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Urogen Pharma has an average rating of "Moderate Buy" and an average target price of $48.78.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the firm's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider owned 119,763 shares in the company, valued at approximately $4,790,520. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 25,222 shares of company stock valued at $892,661. 4.80% of the stock is currently owned by company insiders.

Urogen Pharma News Summary

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: HC Wainwright significantly raised its FY2026 EPS forecast to a loss of $0.83 from a loss of $1.70. The firm also narrowed projected Q3 2026 and Q4 2026 losses to $0.07 and $0.01 per share, respectively. HC Wainwright FY2026 estimate update
• Positive Sentiment: The analyst now expects UroGen to reach profitability earlier than previously forecast, with estimates of $0.01 EPS in Q1 2027 and $0.17 EPS in Q2 2027, compared with prior loss estimates of $0.26 and $0.02 per share. HC Wainwright 2027 quarterly estimate update
• Positive Sentiment: HC Wainwright more than doubled its FY2027 EPS forecast to $1.05 from $0.50, while raising its Q3 2027 estimate to $0.36 from $0.28 and Q4 2027 to $0.50 from $0.49. These revisions strengthen the expected long-term earnings outlook. HC Wainwright FY2027 estimate update
• Neutral Sentiment: UroGen’s latest quarterly revenue of $72.46 million exceeded the $63.55 million consensus estimate, although its $0.28-per-share loss was slightly worse than the expected $0.26 loss. The mixed result makes the improved forward estimates particularly important to investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source